247 related articles for article (PubMed ID: 17911111)
1. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.
Wang Y; Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(46):33247-33251. PubMed ID: 17911111
[TBL] [Abstract][Full Text] [Related]
2. The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator.
Chen EY; Bartlett MC; Loo TW; Clarke DM
J Biol Chem; 2004 Sep; 279(38):39620-7. PubMed ID: 15272010
[TBL] [Abstract][Full Text] [Related]
3. Correctors promote folding of the CFTR in the endoplasmic reticulum.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2008 Jul; 413(1):29-36. PubMed ID: 18361776
[TBL] [Abstract][Full Text] [Related]
4. Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2002 Aug; 277(31):27585-8. PubMed ID: 12070134
[TBL] [Abstract][Full Text] [Related]
5. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2009 Oct; 48(41):9882-90. PubMed ID: 19761259
[TBL] [Abstract][Full Text] [Related]
6. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants.
Wang Y; Loo TW; Bartlett MC; Clarke DM
Biochem J; 2007 Sep; 406(2):257-63. PubMed ID: 17535157
[TBL] [Abstract][Full Text] [Related]
7. Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Sep; 279(37):38395-401. PubMed ID: 15247215
[TBL] [Abstract][Full Text] [Related]
8. The cystic fibrosis V232D mutation inhibits CFTR maturation by disrupting a hydrophobic pocket rather than formation of aberrant interhelical hydrogen bonds.
Loo TW; Clarke DM
Biochem Pharmacol; 2014 Mar; 88(1):46-57. PubMed ID: 24412276
[TBL] [Abstract][Full Text] [Related]
9. Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR).
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2008 Oct; 283(42):28190-7. PubMed ID: 18708637
[TBL] [Abstract][Full Text] [Related]
10. Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
Loo TW; Bartlett MC; Clarke DM
Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419
[TBL] [Abstract][Full Text] [Related]
11. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones.
Wang Y; Loo TW; Bartlett MC; Clarke DM
Mol Pharmacol; 2007 Mar; 71(3):751-8. PubMed ID: 17132688
[TBL] [Abstract][Full Text] [Related]
12. Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR.
Loo TW; Clarke DM
Biochem Pharmacol; 2017 Jul; 136():24-31. PubMed ID: 28366727
[TBL] [Abstract][Full Text] [Related]
13. Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump.
Loo TW; Bartlett MC; Shi L; Clarke DM
Biochem Pharmacol; 2012 Feb; 83(3):345-54. PubMed ID: 22138447
[TBL] [Abstract][Full Text] [Related]
14. A chemical corrector modifies the channel function of F508del-CFTR.
Kim Chiaw P; Wellhauser L; Huan LJ; Ramjeesingh M; Bear CE
Mol Pharmacol; 2010 Sep; 78(3):411-8. PubMed ID: 20501743
[TBL] [Abstract][Full Text] [Related]
15. Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(44):32043-52. PubMed ID: 17848563
[TBL] [Abstract][Full Text] [Related]
16. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
17. An overview on chemical structures as ΔF508-CFTR correctors.
Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
[TBL] [Abstract][Full Text] [Related]
18. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.
Wang Y; Bartlett MC; Loo TW; Clarke DM
Mol Pharmacol; 2006 Jul; 70(1):297-302. PubMed ID: 16624886
[TBL] [Abstract][Full Text] [Related]
19. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2003 Apr; 278(16):13603-6. PubMed ID: 12609990
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.
Mills AD; Yoo C; Butler JD; Yang B; Verkman AS; Kurth MJ
Bioorg Med Chem Lett; 2010 Jan; 20(1):87-91. PubMed ID: 19954980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
